Who is sponsoring NCT00698984?

NCT00698984 is sponsored by dsm-firmenich Switzerland AG.

What condition does NCT00698984 study?

NCT00698984 studies Osteoporosis.

What drugs are being tested in NCT00698984?

Interventions: BONISTEIN(R) bone blend, Placebo.

What is the status of NCT00698984?

NCT00698984 is currently COMPLETED.

Last reviewed 2009-01-15 · How we verify

Pilot Study To Investigate The Effect Of Bonistein(R) Bone Blend Containing Genistein, Polyunsaturated Fatty Acids (N-3 PUFAS) And Vitamins K1 And D3 On Bone Mineral Density (BMD), Bone Mineral Content (BMC) And Biomarkers Of Bone Health In Early Postmenopausal Women

NCT00698984 NA COMPLETED

The purpose of this study is to obtain information about the effect of a combination of genistein, PUFAs, vitamin K and D (BONISTEIN(R) bone blend) on bone health, determined as bone mass density/content and bone biomarkers after 6-months treatment in 70 healthy postmenopausal women. In addition, safety and tolerability will be investigated.

Details

Lead sponsor	dsm-firmenich Switzerland AG
Phase	NA
Status	COMPLETED
Enrolment	70
Start date	2007-01
Completion	2009-01

Conditions

Osteoporosis

Interventions

BONISTEIN(R) bone blend
Placebo

Primary outcomes

Bone Mineral Density/Content (BMD/BMC) at lumbar spine and femoral neck — Baseline and after 6 months

Countries

United States